Vertex Pharmaceuticals (VRTX) Operating Income (2009 - 2026)

Vertex Pharmaceuticals has reported Operating Income for 18 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Operating Income rose 80.62% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.7 billion (up 730.65% YoY), and the FY2025 full-year result was $4.2 billion, up 1891.88% from the prior year.
• Operating Income for Q1 2026 stood at $1.1 billion, down from $1.2 billion in the prior quarter.
• The five-year high for Operating Income was $1.2 billion in Q4 2025, with the low at -$3.5 billion in Q2 2024.
• Average Operating Income over 5 years is $777.5 million, with a median of $1.0 billion recorded in 2022.
• Year-over-year, Operating Income surged 3019.0% in 2022 and slumped 442.43% in 2024.
• Tracing VRTX's Operating Income over 5 years: stood at $1.0 billion in 2022, then fell by 4.35% to $988.5 million in 2023, then gained by 3.79% to $1.0 billion in 2024, then increased by 17.53% to $1.2 billion in 2025, then declined by 5.62% to $1.1 billion in 2026.
• The last three Operating Income figures came in at $1.1 billion (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.

Peer Comparison